BioNTech to Proceed with Site Closures After Failing to Find Buyer
Dow Jones
Sep 28
BioNTech said it would proceed with the closure of sites after it couldn't reach agreements to sell the facilities.
"Despite the intensive efforts of all parties involved and a broad-based sales process, it was unfortunately not possible to realize a sale," the company said Monday.
In May, BioNTech said it would exit its Idar-Oberstein and Marburg sites in Germany, as well as its operations in Singapore and other facilities owned by CureVac before its acquisition, but that it would explore options for a partial or total sale for each. The company said at the time it expected the decision to affect up to 1,860 positions in total.
The company said in August that a fund advised by Dubag Group would acquire its JPT Peptide Technologies subsidiary to ensure the business's continuity.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.